The project, which will break ground immediately, will be located on the company's 40-building campus straddling the border of North Brunswick and New Brunswick. Besides the price tag and the fact that the R&D facility will consist of two buildings, few details were released. The operation, however, will create 120 jobs, replacing many of those trimmed last month when Bristol-Myers Squibb shut down its last on-site manufacturing plant.
DiFrancesco's remarks at the press conference included references to New Jersey's impact on the pharmaceuticals business. "New Jersey companies create almost 40% of all new drugs approved by the FDA," he reported, "and we produce half of worldwide drug sales. These companies also commit half of the $29 billion spent annually on pharmaceuticals R&D." Bristol-Myers Squibb's R&D budget last year was $2 billion.
Want to continue reading?
Become a Free ALM Digital Reader.
Once you are an ALM Digital Member, you’ll receive:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
